Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review-Reference-Cited by-同舟云学术

Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review

Published:2023-02 Issue: Volume: Page:
ISSN:2214-3882
Container-title:Asian Journal of Urology
language:en
Short-container-title:Asian Journal of Urology

Author:

Salciccia Stefano,Frisenda Marco,Bevilacqua Giulio,Viscuso Pietro,Casale Paolo,De Berardinis Ettore,Di Pierro Giovanni Battista,Cattarino Susanna,Giorgino Gloria,Rosati Davide,Del Giudice Francesco,Sciarra Alessandro,Mariotti Gianna,Gentilucci Alessandro

Publisher

Elsevier BV

Reference51 articles.

1. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A;Sciarra;Prostate,2004

2. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores;Briganti;Eur Urol,2012

3. Development and internal validation of a novel model to identify the candidates for extended pelvic lymph node dissection in prostate cancer;Gandaglia;Eur Urol,2017

4. Critical review of prostate cancer predictive tools;Shariat;Future Oncol,2009

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between the neutrophil-to-lymphocyte ratio and type 2 diabetes mellitus: a cross-sectional study;BMC Endocrine Disorders;2024-07-09

2. Prediction Model for Gestational Diabetes Mellitus Based on Routine Antenatal Care: Progress and Prospects;Advances in Clinical Medicine;2024

3. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu–PSMA-617;Medicine;2023-11-24